申请人:GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD
公开号:EP3272742A1
公开(公告)日:2018-01-24
A compound represented by Formula I or pharmaceutically acceptable salt thereof. The present invention relates to a 4-arylamino quinazoline hydroxamic acid compound having a histone deacetylase inhibitory activity, preparation method of the compound, pharmaceutical composition comprising the compound, and use of the compound and the pharmaceutical composition in the preparation of a histone deacetylase inhibitor medicine. The present invention aims at acquiring, via a medicine design and a synthetic technology, a series of selective histone deacetylase inhibitors having good hypotype selectivity and favorable pharmacokinetic characteristics based on optimization of an enzyme surface recognition region and connection region of 4-arylamino quinazoline, thus reducing an effect on normal tissues or cells while improving an antineoplastic activity of the normal tissues or cells.
一种由式 I 代表的化合物或其药学上可接受的盐。本发明涉及一种具有组蛋白去乙酰化酶抑制活性的 4-芳基氨基喹唑啉羟肟酸化合物、该化合物的制备方法、包含该化合物的药物组合物,以及该化合物和药物组合物在制备组蛋白去乙酰化酶抑制剂药物中的用途。本发明的目的是通过药物设计和合成技术,在优化4-芳基氨基喹唑啉的酶表面识别区和连接区的基础上,获得一系列选择性组蛋白去乙酰化酶抑制剂,这些抑制剂具有良好的低分型选择性和良好的药代动力学特征,从而在提高正常组织或细胞的抗肿瘤活性的同时,降低对正常组织或细胞的影响。